JP2024512765A - トール様受容体アゴニストを使用したがん治療 - Google Patents

トール様受容体アゴニストを使用したがん治療 Download PDF

Info

Publication number
JP2024512765A
JP2024512765A JP2023560819A JP2023560819A JP2024512765A JP 2024512765 A JP2024512765 A JP 2024512765A JP 2023560819 A JP2023560819 A JP 2023560819A JP 2023560819 A JP2023560819 A JP 2023560819A JP 2024512765 A JP2024512765 A JP 2024512765A
Authority
JP
Japan
Prior art keywords
administered
tlr9 agonist
dose
liver
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023560819A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024512765A5 (cg-RX-API-DMAC7.html
Inventor
スティーブン・シー・カッツ
ブライアン・エフ・コックス
デイビッド・ベンジャミン・ジャロク
Original Assignee
トリサルース・ライフ・サイエンシズ・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トリサルース・ライフ・サイエンシズ・インコーポレイテッド filed Critical トリサルース・ライフ・サイエンシズ・インコーポレイテッド
Publication of JP2024512765A publication Critical patent/JP2024512765A/ja
Publication of JP2024512765A5 publication Critical patent/JP2024512765A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2023560819A 2021-04-01 2022-03-31 トール様受容体アゴニストを使用したがん治療 Pending JP2024512765A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163169674P 2021-04-01 2021-04-01
US63/169,674 2021-04-01
US202263298589P 2022-01-11 2022-01-11
US63/298,589 2022-01-11
PCT/US2022/022801 WO2022212690A1 (en) 2021-04-01 2022-03-31 Cancer therapy using toll-like receptor agonists

Publications (2)

Publication Number Publication Date
JP2024512765A true JP2024512765A (ja) 2024-03-19
JP2024512765A5 JP2024512765A5 (cg-RX-API-DMAC7.html) 2025-04-08

Family

ID=83456830

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023560819A Pending JP2024512765A (ja) 2021-04-01 2022-03-31 トール様受容体アゴニストを使用したがん治療

Country Status (7)

Country Link
EP (1) EP4313315A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024512765A (cg-RX-API-DMAC7.html)
KR (1) KR20240004419A (cg-RX-API-DMAC7.html)
AU (1) AU2022249092A1 (cg-RX-API-DMAC7.html)
CA (1) CA3215582A1 (cg-RX-API-DMAC7.html)
DE (1) DE112022001882T9 (cg-RX-API-DMAC7.html)
WO (1) WO2022212690A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN121568740A (zh) * 2023-04-06 2026-02-24 特萨乐斯生命科学公司 用于提供局部湍流以递送医用栓塞剂的系统和装置

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210030783A1 (en) * 2018-02-13 2021-02-04 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1364010B1 (en) 2000-12-27 2010-06-16 Dynavax Technologies Corporation Immunomodulatory polynucleotides and methods of using the same
US20040009151A1 (en) * 2002-04-04 2004-01-15 Kay Mark A. Methods for delivering recombinant adeno-associated virus virions to the liver of a mammal
US8158768B2 (en) 2002-12-23 2012-04-17 Dynavax Technologies Corporation Immunostimulatory sequence oligonucleotides and methods of using the same
US7963956B2 (en) * 2003-04-22 2011-06-21 Antisense Pharma Gmbh Portable equipment for administration of fluids into tissues and tumors by convection enhanced delivery technique
US8696698B2 (en) 2009-12-02 2014-04-15 Surefire Medical, Inc. Microvalve protection device and method of use for protection against embolization agent reflux
US8500775B2 (en) 2009-12-02 2013-08-06 Surefire Medical, Inc. Protection device and method against embolization agent reflux
US9539081B2 (en) 2009-12-02 2017-01-10 Surefire Medical, Inc. Method of operating a microvalve protection device
US9770319B2 (en) 2010-12-01 2017-09-26 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
US9968740B2 (en) 2014-03-25 2018-05-15 Surefire Medical, Inc. Closed tip dynamic microvalve protection device
HUE053145T2 (hu) * 2014-12-31 2021-06-28 Checkmate Pharmaceuticals Inc Kombinált tumor immunterápia
US20160287839A1 (en) 2015-03-31 2016-10-06 Surefire Medical, Inc. Apparatus and Method for Infusing an Immunotherapy Agent to a Solid Tumor for Treatment
EP3302501B1 (en) * 2015-05-29 2021-09-22 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and cpg-c type oligonucleotide for treating cancer
CA3020873A1 (en) * 2016-04-15 2017-10-19 Dynavax Technologies Corporation Intratumoral administration of particles containing a toll-like receptor 9 agonist and a tumor antigen for treating cancer
US10806893B2 (en) 2017-01-10 2020-10-20 Surefire Medical, Inc. Guiding catheter having shape-retentive distal end
US10588636B2 (en) 2017-03-20 2020-03-17 Surefire Medical, Inc. Dynamic reconfigurable microvalve protection device
US20190298983A1 (en) 2018-01-15 2019-10-03 Surefire Medical, Inc. Injection Port for Therapeutic Delivery
US11850398B2 (en) 2018-08-01 2023-12-26 Trisalus Life Sciences, Inc. Systems and methods for pressure-facilitated therapeutic agent delivery
US12433597B2 (en) 2019-06-04 2025-10-07 Trisalus Life Sciences, Inc. Atraumatic occlusive system with compartment for measurement of vascular pressure change
US20220249389A1 (en) * 2019-07-12 2022-08-11 Oregon Health & Science University Immunotherapeutic constructs and methods of their use
US12686870B2 (en) * 2020-01-10 2026-07-21 Sbi Biotech Co., Ltd. TLR9 agonists
AU2021347154A1 (en) * 2020-09-22 2023-05-11 Trisalus Life Sciences, Inc. Cancer therapy using toll-like receptor agonists

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210030783A1 (en) * 2018-02-13 2021-02-04 Checkmate Pharmaceuticals, Inc. Compositions and methods for tumor immunotherapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CANCER DISCOVERY, vol. Volume 8, Issue 10, JPN6026016515, 2018, pages 1250 - 1257, ISSN: 0005856063 *
JOURNAL OF EXPERIMENTAL &CLINICAL CANCER RESEARCH, vol. Volume 40,Article 13, JPN6026016514, 6 January 2021 (2021-01-06), ISSN: 0005856062 *
ONCOLOGIC RESEARCH, vol. Volume 23, Issue 6, JPN6026016513, 2016, pages 321 - 326, ISSN: 0005856061 *

Also Published As

Publication number Publication date
CA3215582A1 (en) 2022-10-06
DE112022001882T9 (de) 2024-02-29
DE112022001882T5 (de) 2024-01-18
WO2022212690A1 (en) 2022-10-06
KR20240004419A (ko) 2024-01-11
AU2022249092A9 (en) 2023-10-26
AU2022249092A1 (en) 2023-10-12
EP4313315A1 (en) 2024-02-07
EP4313315A4 (en) 2025-02-19

Similar Documents

Publication Publication Date Title
EP3057990B1 (en) Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody
JP2023542988A (ja) トール様受容体アゴニストを使用したがん治療
US20240180952A1 (en) Cancer therapy using toll-like receptor agonists
TWI451875B (zh) 用於治療先前治療過之乳癌之抗-血管新生療法
KR20240004419A (ko) 톨-유사 수용체 작용제를 사용한 암 요법
JP2023542989A (ja) トール様受容体アゴニストを使用したがん治療
KR20230033647A (ko) 난소암 백신에서 백혈병 유래 세포의 용도
HK40107087A (en) Cancer therapy using toll-like receptor agonists
CN116685330A (zh) 使用toll样受体激动剂的癌症疗法
HK40100192A (en) Cancer therapy using toll-like receptor agonists
US20250101438A1 (en) Methods of treating immune dysfunction in liver cancer with toll-like receptor agonists
HK40096714A (en) Cancer therapy using toll-like receptor agonists
KR20200019229A (ko) B형 간염 바이러스 감염을 특징으로 하는 간세포 암종의 치료
WO2025096686A1 (en) Methods of treating pancreatic ductal adenocarcinoma with a toll-like receptor 9 agonist
KR20240004703A (ko) 체크포인트 저해제를 이용한 암 치료요법
HK40106247A (en) Cancer therapy using checkpoint inhibitors
JP2025507126A (ja) 脂肪組織を画像化するための方法および材料
HK1227888A1 (en) Compositions comprising a combination of a vegf antagonist and an anti-ctla-4 antibody

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250331

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250331

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260512